SG11202109830TA - Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics - Google Patents

Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Info

Publication number
SG11202109830TA
SG11202109830TA SG11202109830TA SG11202109830TA SG 11202109830T A SG11202109830T A SG 11202109830TA SG 11202109830T A SG11202109830T A SG 11202109830TA SG 11202109830T A SG11202109830T A SG 11202109830TA
Authority
SG
Singapore
Prior art keywords
pah
therapeutics
viral dna
dna vectors
phenylalanine hydroxylase
Prior art date
Application number
Inventor
Douglas Anthony Kerr
Phillip Samayoa
Nathaniel Silver
Matthew Chiocco
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of SG11202109830TA publication Critical patent/SG11202109830TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0071Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y114/00Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001Phenylalanine 4-monooxygenase (1.14.16.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11202109830T 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics SG11202109830TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962817771P 2019-03-13 2019-03-13
US201962857514P 2019-06-05 2019-06-05
PCT/US2020/022595 WO2020186150A2 (en) 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Publications (1)

Publication Number Publication Date
SG11202109830TA true SG11202109830TA (en) 2021-10-28

Family

ID=72426457

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109830T SG11202109830TA (en) 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Country Status (12)

Country Link
US (1) US20230024354A1 (en)
EP (1) EP3938515A4 (en)
JP (1) JP2022525302A (en)
KR (1) KR20210149702A (en)
CN (1) CN113874508A (en)
AU (1) AU2020235121A1 (en)
BR (1) BR112021017852A2 (en)
CA (1) CA3133330A1 (en)
IL (1) IL286283A (en)
MX (1) MX2021011037A (en)
SG (1) SG11202109830TA (en)
WO (1) WO2020186150A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4189098A1 (en) 2020-07-27 2023-06-07 Anjarium Biosciences AG Compositions of dna molecules, methods of making therefor, and methods of use thereof
WO2022061000A1 (en) * 2020-09-16 2022-03-24 Generation Bio Co. Closed-ended dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah)
CN115772503B (en) * 2022-08-16 2023-10-17 广东省南山医药创新研究院 Gene modified cell medicine for expressing PAH and preparation method and application thereof
CN116656740A (en) * 2023-05-30 2023-08-29 浙江大学 Adeno-associated virus gene therapy vector and application thereof in preparation of medicament for treating phenylketonuria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149852A2 (en) * 2006-06-19 2007-12-27 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
ES2898337T3 (en) * 2016-03-03 2022-03-07 Univ Massachusetts Closed-ended linear duplex DNA for non-viral gene transfer
KR20190100318A (en) * 2016-12-30 2019-08-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Gene therapy to treat phenylketonuria
CA3056182A1 (en) * 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
US11820999B2 (en) * 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
WO2018222925A1 (en) * 2017-05-31 2018-12-06 Ultragenyx Pharmaceutical Inc. Therapeutics for phenylketonuria
TW201920255A (en) * 2017-08-09 2019-06-01 美商生物化學醫療公司 Nucleic acid molecules and uses thereof

Also Published As

Publication number Publication date
EP3938515A2 (en) 2022-01-19
JP2022525302A (en) 2022-05-12
BR112021017852A2 (en) 2021-11-30
AU2020235121A1 (en) 2021-11-04
IL286283A (en) 2021-10-31
CN113874508A (en) 2021-12-31
EP3938515A4 (en) 2022-12-28
MX2021011037A (en) 2021-12-15
WO2020186150A3 (en) 2020-10-29
WO2020186150A2 (en) 2020-09-17
US20230024354A1 (en) 2023-01-26
CA3133330A1 (en) 2020-09-17
KR20210149702A (en) 2021-12-09

Similar Documents

Publication Publication Date Title
IL286283A (en) Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics
EP3463897A4 (en) Digital printing process and system
EP3931360A4 (en) Systems and methods for using sequencing data for pathogen detection
EP3715461A4 (en) Genome editing composition using crispr/cpf1 system and use thereof
EP3371194A4 (en) Protein sequencing methods and reagents
EP3436576A4 (en) Cell line for recombinant protein and/or viral vector production
EP3686275A4 (en) Gene editing t cell and use thereof
EP3662079A4 (en) Methods of detecting modified and unmodified dna
EP3310919A4 (en) Vectors for use in an inducible coexpression system
EP3359671A4 (en) Dna vectors, transposons and transposases for eukaryotic genome modification
IL284687A (en) Novel fusion proteins specific for cd137 and gpc3
EP3735420A4 (en) Single-domain antibody-cytosine deaminase fusion proteins
EP3565563A4 (en) Nucleic acids and methods for genome editing
EP4031168A4 (en) Synthetic dna vectors and methods of use
IL289254A (en) Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
EP3997205A4 (en) Rna sequencing methods
EP3504280A4 (en) Selective matte and glossy printing
EP3331653A4 (en) Spot gloss and gloss control in an inkjet printing system
IL286284A (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
EP2232258A4 (en) Improved viral protein quantification and vaccine quality control therewith
EP3910066A4 (en) Dna reference standard and use thereof
EP3476945A4 (en) Rna detecting kit and method
EP4000220A4 (en) Methods and apparatus for current sensing and current limiting
EP3491009A4 (en) Protein expression enhancer sequences and use thereof
EP3968630A4 (en) Gradient change detection system, display system using this, and program for moving body